BioLineRx (BLRX) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Jones Trading Reiterates Hold Rating on BioLineRx (BLRX)
May 28, 2025 8:59 AM EDTJones Trading analyst Justin Walsh reiterated a Hold rating on BioLineRx (NASDAQ: BLRX).
The analyst comments "APHEXDA will provide a steady stream of royalties that support earlier stage development of assets expected to be in-licensed in 2025-2026, most likely in the oncology and/or... More



